190 related articles for article (PubMed ID: 36172187)
21. The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer.
Luo X; Zhou Z; Zeng X; Liu Q
Front Pharmacol; 2022; 13():935581. PubMed ID: 35935852
[No Abstract] [Full Text] [Related]
22. A Trial-Based Cost-Effectiveness Analysis of Bevacizumab and Chemotherapy Versus Chemotherapy Alone for Advanced Nonsquamous Non-Small-Cell Lung Cancer in China.
Li X; Li W; Hou L
Value Health Reg Issues; 2019 May; 18():1-7. PubMed ID: 30412913
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness analysis of sintilimab + chemotherapy versus camrelizumab + chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China.
Rui M; Fei Z; Wang Y; Zhang X; Ma A; Sun H; Li H
J Med Econ; 2022; 25(1):618-629. PubMed ID: 35475459
[TBL] [Abstract][Full Text] [Related]
24. Cost-Effectiveness Analysis of Camrelizumab Plus Chemotherapy vs. Chemotherapy Alone as the First-Line Treatment in Patients With IIIB-IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Without EGFR and ALK Alteration from a Perspective of Health - Care System in China.
Zhu C; Xing XX; Wu B; Liang G; Han G; Lin CX; Fang HM
Front Pharmacol; 2021; 12():735536. PubMed ID: 35002693
[No Abstract] [Full Text] [Related]
25. The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer.
Lu T; Huang Y; Cai Z; Lin W; Chen X; Chen R; Hu Y
Front Pharmacol; 2023; 14():1171302. PubMed ID: 37564176
[No Abstract] [Full Text] [Related]
26. First-line versus second-line use of pralsetinib in treatment of rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer: a cost-effectiveness analysis.
Liu W; Huo G; Li M; Chen P
Transl Lung Cancer Res; 2023 Sep; 12(9):1949-1958. PubMed ID: 37854153
[TBL] [Abstract][Full Text] [Related]
27. Cost-Utility Analysis of Camrelizumab Plus Chemotherapy Versus Chemotherapy Alone as a First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer in China.
Chen T; Xie R; Zhao Q; Cai H; Yang L
Front Oncol; 2022; 12():746526. PubMed ID: 35936702
[TBL] [Abstract][Full Text] [Related]
28. Cost-Effectiveness Analysis of Atezolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer With Different PD-L1 Expression Status.
Liu G; Kang S; Wang X; Shang F
Front Oncol; 2021; 11():669195. PubMed ID: 33987103
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness analysis of first-line treatments for advanced epidermal growth factor receptor-mutant non-small cell lung cancer patients.
Li WQ; Li LY; Chai J; Cui JW
Cancer Med; 2021 Mar; 10(6):1964-1974. PubMed ID: 33626238
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness analysis of sintilimab vs. placebo in combination with chemotherapy as first-line therapy for local advanced or metastatic oesophageal squamous cell carcinoma.
Shao T; Zhao M; Tang W
Front Oncol; 2022; 12():953671. PubMed ID: 36561521
[TBL] [Abstract][Full Text] [Related]
32. Cemiplimab combined with chemotherapy
Zhu G; Cai H; Zheng Z
Ther Adv Med Oncol; 2023; 15():17588359231213619. PubMed ID: 38028144
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of camrelizumab plus chemotherapy vs. chemotherapy in the first-line treatment of non-squamous NSCLC: Evidence from China.
Dai H; Wang W; Fan X; Chen Y
Front Med (Lausanne); 2023; 10():1122731. PubMed ID: 36865055
[TBL] [Abstract][Full Text] [Related]
34. Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer.
Lam SW; Wai M; Lau JE; McNamara M; Earl M; Udeh B
Pharmacotherapy; 2017 Jan; 37(1):94-103. PubMed ID: 27870079
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China.
Zhou D; Luo X; Zhou Z; Zeng X; Wan X; Tan C; Liu Q
Front Pharmacol; 2022; 13():880280. PubMed ID: 36091746
[No Abstract] [Full Text] [Related]
36. Atezolizumab compared to chemotherapy for first-line treatment in non-small cell lung cancer with high PD-L1 expression: a cost-effectiveness analysis from US and Chinese perspectives.
Cheng S; Pei R; Li J; Li B; Tang L; Yin T; Liu S
Ann Transl Med; 2021 Sep; 9(18):1481. PubMed ID: 34734033
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer.
Courtney PT; Yip AT; Cherry DR; Salans MA; Kumar A; Murphy JD
JAMA Netw Open; 2021 May; 4(5):e218787. PubMed ID: 33938936
[TBL] [Abstract][Full Text] [Related]
38. The effect of PD-L1 categories-directed pembrolizumab plus chemotherapy for newly diagnosed metastatic non-small-cell lung cancer: a cost-effectiveness analysis.
Wu B; Lu S
Transl Lung Cancer Res; 2020 Oct; 9(5):1770-1784. PubMed ID: 33209600
[TBL] [Abstract][Full Text] [Related]
39. Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer.
Ding D; Hu H; Liao M; Shi Y; She L; Yao L; Zhu Y; Zeng S; Huang J
Adv Ther; 2020 May; 37(5):2116-2126. PubMed ID: 32193809
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
Wu B; Chen H; Shen J; Ye M
Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]